Broccoli extract lowers blood sugar for type 2 diabetes patients
- Author: Joanne Flowers Jun 16, 2017,
Jun 16, 2017, 13:35
The team constructed a signature for Type 2 diabetes based on 50 genes and then used publically available expression data sets to screen 3,852 compounds for drugs that potentially reverse the disease. "This could lead to elevated fasting blood glucose and manifest diabetes".'The most important therapy for type 2 diabetes is lifestyle changes - such as eating healthily and being physically active. They should also have a low glycemic index score which means that they won't cause sudden spikes in your blood sugar levels.
The humble broccoli, which is often disliked by many people for being boring, is now being touted as a superfood vegetable. The findings showed that broccoli, which is also rich in sulforaphane, a naturally occurring compound found in cruciferous vegetables, may help reverse the disease signature.
(Online) - An effective new treatment for type 2 diabetes could be sitting in your fridge, according to the results of a new study. The scientists found that treating rat liver cells with the said compound could lessen the blood sugar levels. "We saw a reduction of glucose of about 10 percent, which is sufficient to reduce complications in the eyes, kidneys, and blood".
"We're very excited about the effects we've seen and are eager to bring the extract to patients", study coauthor Anders Rosengren of the University of Gothenburg in Sweden tells New Scientist.
Broccoli extract is complementary to metformin, not competitive. In obese individuals the liver becomes insensitive to this normal regulation and starts producing more glucose than is actually needed.
They also found that sulforaphane lowers blood glucose levels in a completely different way from metformin.
The team found that on average, participants who received sulforaphane had 10% lower blood glucose levels those in the control group (who received placebos). When the researchers gave concentrated broccoli sprout extracts to 97 human type 2 diabetes patients in a 12-week randomized placebo-controlled trial, obese participants who entered the study with dysregulated disease demonstrated significantly decreased fasting blood glucose levels compared to controls.